In in vitro studies we evaluated the susceptibilities of 13-lactamase-producing and -nonproducing, ampicillinresistant strains of Haemophilus influenzae and compared them with those of ampicillin-susceptible strains. Ampicillin, amoxicillin-clavulanic acid, ceftibuten, cefaclor, cefuroxime, cefixime, and cefotaxime were evaluated by broth microdilution tests and disk diffusion tests. The disk diffusion tests accurately categorized 1-lactamase-producing strains and ampicillin-susceptible strains as being susceptible to the study drugs other than ampicillin. Ampicillin-resistant, 13-lactamase-nonproducing strains were relatively resistant to all seven study drugs, but the disk diffusion test did not always predict that resistance. The clinical relevance of the decreased susceptibility to various agents remains unclear, but to be conservative, all ampicillin-resistant, P-lactamase-nonproducing strains might be assumed to be resistant to other 13-lactams. After excluding that small group of isolates, reliable susceptibility test results were obtained with lots of Haemophilus Test Medium that met quality assurance criteria.
tions caused by Haemophilus influenzae, but its usefulness has been compromised by the increasing prevalence of ampicillin-resistant strains. Different medical centers throughout the world report that 15 to 30% of their H. influenzae isolates are resistant to ampicillin (4, 9, 18) . Nearly all of the ampicillin-resistant H. influenzae isolates are capable of producing a TEM-like ,-lactamase enzyme which can inactivate ampicillin. That enzyme can also inactivate other penicillins and some cephalosporins, but the rate of inactivation may vary with different drugs. A ,B-lactamase inhibitor such as clavulanic acid irreversibly binds to the 13-lactamase enzymes, thus rendering the microorganism susceptible to a coadministered penicillin. Amoxicillin and clavulanic acid have been combined for clinical use, and that combination is effective against 13-lactamase-producing, ampicillin-resistant strains of H. influenzae as well as ampicillin-susceptible, ,B-lactamase-nonproducing strains.
Some strains of H. influenzae have developed resistance to ampicillin by virtue of a mechanism other than 3-lactamase production. Such ampicillin-resistant, 3-lactamasenonproducing (Ampr NBLP) strains probably represent <1% of all H. influenzae isolates recovered in the United States (4, 9, 18), but they are becoming more prevalent in the United Kingdom (19) . Ampr NBLP strains are thought to have altered penicillin-binding proteins with decreased affinities for ampicillin and other ,-lactams (13, 14, 18 (2, 3, 8, 16, 17) . Interpretive criteria for microdilution tests and disk diffusion tests were those described in the current National Committee for Clinical Laboratory Standards documents (16, 17) . Interpretive criteria for ceftibuten are not yet included in those documents, and thus, tentative interpretive criteria were those described previously (1, 6) for testing other species on unsupplemented Mueller-Hinton agar.
RESULTS
Susceptibility test results with Ampr NBLP, j-lactamaseproducing, and ampicillin-susceptible strains of H. influenzae are contrasted in Fig. 1 (18) . ,3-Lactamase-negative strains for which ampicillin MICs are .4.0 ,ug/ml are categorized as Ampr NBLP H.
influenzae strains, and they may be assumed to be relatively resistant to most other ,3-lactams. Strains for which ampicillin MICs are intermediate (2.0 ,ug/ml) are difficult to categorize and should be retested.
Heelan et al. (5) found ampicillin to be unreliable since most NBLP strains that appear to be resistant or intermediate in susceptibility by disk diffusion tests have proven to be susceptible by MIC determinations. In our experience, all Ampr NBLP and all ,B-lactamase-positive strains were resistant or intermediate in susceptibility and all of our ampicillinsusceptible strains were susceptible by the disk diffusion test. That is in conflict with the results of Mendelman et al. (11, 15) , who reported that 10-,ug ampicillin disks fail to detect Amp' NBLP strains consistently. However, they used previously recommended interpretive criteria and performed their studies before the current quality assurance criteria were defined (2, 3, 8 because the MICs were < 1.0 ptg/ml, and thus, they proposed decreasing the zone size breakpoint to .21 mm for the susceptible category. In our hands, 9 of 20 Ampr NBLP strains were unequivocally resistant to cefixime (MIC, >4.0 ,ug/ml) but had inhibition zone diameters of .21 mm. With the current breakpoint of .30 mm for susceptibility, 16 of 20 Ampr NBLP strains were resistant to cefixime, and we judge that categorization to be the most appropriate. Whether that in vitro resistance is clinically relevant remains to be seen.
Some Ampr NBLP strains are likely to show clinical resistance because the MICs for the strains exceed the MIC interpretive breakpoints for susceptibility, but strains for which MICs are increased only slightly are difficult to evaluate. There is relatively little information about the clinical importance of in vitro observations with Ampr NBLP strains. In the United States, Ampr NBLP strains of H. influenzae are very uncommon, but they may become more prevalent in the future, and then the problem of interpreting in vitro data will become much more critical. In the interim, it might be prudent to assume that all Ampr NBLP strains are resistant to all P-lactam antimicrobial agents, regardless of the results of in vitro tests with those agents. With the exclusion of Ampr NBLP strains, reliable disk diffusion and broth microdilution susceptibility tests were obtained when using lots of Haemophilus Test Medium that meet quality assurance criteria.
